What is LGVN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LGVN?

P/E (TTM) is n/a and 52-week range is $2.30 to $12.30 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LGVN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for LGVN?

The company profile lists revenue (TTM) near $12M, net income (TTM) near $-23.64B, EPS (TTM) near $-6.72 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Longeveron Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Miami, Florida, US, 31.6M shares outstanding, ISIN US54303L2034 when available from company profile and filing metadata.

Longeveron Inc

$LGVN

Health Care · Biotechnology

IR Run Scenarios

$2.48

+4.64%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. The company is headquartered in Miami, Florida and currently employs 26 full-time employees. The company went IPO on 2021-02-12. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The firm is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.

Employees

Website

www.longeveron.com/

IPO

2021-02-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)